Becton Dickinson and Co  

(Public, NYSE:BDX)   Watch this stock  
Find more results for BDX
181.95
-0.07 (-0.04%)
After Hours: 181.95 0.00 (0.00%)
Feb 22, 4:40PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 181.13 - 182.58
52 week 144.73 - 182.65
Open 181.33
Vol / Avg. 649,887.00/1.01M
Mkt cap 38.96B
P/E 30.23
Div/yield 0.73/1.60
EPS 6.02
Shares 212.83M
Beta 1.00
Inst. own 85%
Feb 1, 2017
Q1 2017 Becton Dickinson and Co Earnings Release (Estimated)
Jan 25, 2017
Becton Dickinson and Co Annual Shareholders Meeting (Estimated)
Jan 24, 2017
Becton Dickinson and Co Annual Shareholders Meeting
Nov 29, 2016
Becton Dickinson and Co at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 19.20% 7.83%
Operating margin 27.75% 11.46%
EBITD margin - 26.21%
Return on average assets 9.02% 3.75%
Return on average equity 29.63% 13.19%
Employees 50,900 -
CDP Score - 94 B

Address

1 Becton Dr
FRANKLIN LAKES, NJ 07417-1815
United States - Map
+1-201-8476800 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.

Officers and directors

Vincent A. Forlenza Chairman of the Board, President, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Christopher R. Reidy Chief Financial Officer, Executive Vice President, Chief Administrative Officer
Age: 59
Bio & Compensation  - Reuters
Nabil Shabshab Executive Vice President,Strategic Planning Chief Marketing Officer
Age: 51
Bio & Compensation  - Reuters
Jeffrey S. Sherman Executive Vice President, General Counsel
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Gary M. Cohen Executive Vice President and President, Global Health.
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Alexandre Conroy Executive Vice President and President, Europe, EMA
Age: 53
Bio & Compensation  - Reuters
James Lim Executive Vice President and President, Greater Asia
Age: 52
Bio & Compensation  - Reuters
Thomas E. Polen Executive Vice President and President - Medical
Age: 43
Bio & Compensation  - Reuters
Stephen Sichak Jr. Executive Vice President,Integrated Supply Chain.
Age: 59
Bio & Compensation  - Reuters
Ellen Strahlman M.D. Executive Vice President, Research and Development and Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters